Guardant Health

guardanthealth.com →

+30%

est. 2Y upside i

HealthcareIPO

Rank

#2839

Sector

Biotechnology

Est. Liquidity

~1Y

Data Quality

Data: High

Guardant Health presents a moderate upside opportunity for a job seeker, driven by its strong position in the growing precision oncology market and promising multi-cancer early detection pipeline.

Last updated: March 10, 2026

Bull (25%)+100%

Guardant Health's Shield test achieves widespread payer adoption and strong market penetration, significantly accelerating multi-cancer early detection (MCED) revenue beyond current projections. Combined with sustained 30%+ growth in its core oncology business and successful FDA approvals for Guardant360 streamlining offerings, the company reaches $2.5B+ revenue by 2028, justifying a $24.4B+ valuation at a premium multiple.

Base (46%)+35%

Guardant Health maintains its leadership in precision oncology, with Guardant360 and Reveal continuing strong growth (25-30% YoY). Shield gains traction but faces slower-than-expected reimbursement and adoption, leading to overall revenue growth of 25-30% to approximately $1.7B by 2028. The company improves cash burn, but profitability remains elusive, resulting in a valuation of around $16.5B, in line with analyst consensus.

Bear (29%)-40%

Increased competition from incumbents like Exact Sciences and Natera, coupled with slower-than-anticipated reimbursement and adoption for Shield, stifles growth. Continued high cash burn and potential further dilution from equity raises lead to investor skepticism. Revenue growth decelerates below 20%, and the company struggles to achieve profitability, resulting in a down-round or a significant market cap contraction to $7.3B, wiping out a substantial portion of common stock value.

Est. time to liquidity~0.5 years

Preference Stack Risk

high

Funding Intensity

16%

Investors hold $1.9 billion in liquidation preferences, which represents 15.6% of the current $12.2 billion valuation.

Dilution Risk

high

The company continues to incur significant losses and reported a $510.17 million shelf registration for common shares in February 2026, indicating potential future dilution.

Secondary Liquidity

active

As a publicly traded company, Guardant Health's shares are actively traded on the NASDAQ, providing liquidity for vested equity (subject to any lock-up periods).

Questions to Ask at the Interview

Strategic questions based on Guardant Health's data — designed to show you've done your homework.

1
“Given the high incumbent threat from companies like Exact Sciences and Natera, how does Guardant Health plan to maintain and expand its market share, particularly for the Shield test, over the next 2-3 years?”
2
“With 2026 revenue guidance at $1.25-$1.28 billion and continued cash burn, what is the company's detailed path to profitability, and what key milestones should employees expect to see in the next 24 months?”
3
“Considering the recent shelf registration for common shares and the existing preference stack, how does Guardant Health plan to manage potential dilution for common stock holders, and what is the expected timeline for employees to realize liquidity from their equity grants?”

Community

Valuation Sentiment

Our model estimates +30% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.